challenges
Agitation and aggression are common to many disorders of the brain and mind and encompass a range of disruptive behaviours such as verbal outbursts, physically harmful actions, restlessness, repetitive behaviours, and excessive negativity. These symptoms can leave patients socially isolated and pose a major challenge for carers
solution
Kinoxis' lead compound is in Phase 1 clinical trials for agitation in dementia, aiming to enter Phase 2 trials in 2027.
You might also like
For founders
Building for the systems that matter? Pitch us.
We back founders turning breakthrough science into category-defining companies.
For investors
Invest with Main Sequence
Access Australia's deep tech frontier alongside us.











